Literature DB >> 11741248

Nonlinearity detection: advantages of nonlinear mixed-effects modeling.

E N Jonsson1, J R Wade, M O Karlsson.   

Abstract

The purpose of this study was to address the question of whether the use of nonlinear mixed-effect models has an impact on the detection and characterization of nonlinear processes (pharmacokinetic and pharmacodynamic) in rich data obtained from a few subjects. Simulations were used to assess the difference between applying population analysis, ie, nonlinear mixed-effects models as implemented in NONMEM, and the standard 2-stage (STS) method as the data analysis method for detection and characterization of nonlinearities. Three situations were considered, 2 pharmacokinetic and 1 pharmacodynamic. Both the first-order (FO) and FO conditional estimation (FOCE) algorithms were used for the population analyses. Within each situation, rich data were simulated for 8 subjects at multiple dose levels. The true nonlinear model and a simpler linear model were fit to each data set using each of the STS, FO, and FOCE methods. Criteria were prespecified to determine when each data analysis method detected the true nonlinear model. For all 3 simulated situations, the application of population analysis with the FOCE algorithm enabled the detection and characterization of the true nonlinear models in at least a 4-fold lower dose level than the STS approach. For both of the pharmacokinetic settings, population analysis with the FO algorithm performed much more poorly than the STS approach. The superior detection and characterization of nonlinearities provided by population analysis with the FOCE algorithm should allow drug developers to better predict and define how a drug should be used in clinical practice in such situations.

Mesh:

Year:  2000        PMID: 11741248      PMCID: PMC2761142          DOI: 10.1208/ps020332

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  16 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Application of NONMEM to routine bioavailability data.

Authors:  D A Graves; I Chang
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

4.  Importance of the use of the appropriate pharmacokinetic model to analyze in vivo enzyme constants.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

5.  On the identification of Michaelis-Menten elimination parameters from a single dose-response curve.

Authors:  K R Godfrey; W R Fitch
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

6.  The deterministic identifiability of nonlinear pharmacokinetic models.

Authors:  K R Godfrey; W R Fitch
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

7.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

8.  A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat.

Authors:  L Aarons; J W Mandema; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

9.  Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients.

Authors:  Y Hashimoto; A Odani; Y Tanigawara; M Yasuhara; T Okuno; R Hori
Journal:  Biol Pharm Bull       Date:  1994-02       Impact factor: 2.233

10.  Nonlinear mixed effect modeling of the pharmacodynamics of natriuretic peptides in rats.

Authors:  Y Hashimoto; S Mori; N Hama; K Nakao; H Imura; M Yamaguchi; M Yasuhara; R Hori
Journal:  J Pharmacokinet Biopharm       Date:  1993-06
View more
  19 in total

1.  The back-step method--method for obtaining unbiased population parameter estimates for ordered categorical data.

Authors:  Maria C Kjellsson; Siv Jönsson; Mats O Karlsson
Journal:  AAPS J       Date:  2004-08-11       Impact factor: 4.009

2.  Using stochastic differential equations for PK/PD model development.

Authors:  Niels Rode Kristensen; Henrik Madsen; Steen Hvass Ingwersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

Review 3.  Population pharmacokinetics/pharmacodynamics of anesthetics.

Authors:  Erik Olofsen; Albert Dahan
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

4.  Randomized exposure-controlled trials; impact of randomization and analysis strategies.

Authors:  Kristin E Karlsson; Anders Grahnén; Mats O Karlsson; E Niclas Jonsson
Journal:  Br J Clin Pharmacol       Date:  2007-04-10       Impact factor: 4.335

Review 5.  Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Authors:  Anthe S Zandvliet; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models.

Authors:  Jurgen B Bulitta; Cornelia B Landersdorfer
Journal:  AAPS J       Date:  2011-03-04       Impact factor: 4.009

7.  Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.

Authors:  Cornelia B Landersdorfer; Yan-Ling He; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

8.  An Algorithm and R Program for Fitting and Simulation of Pharmacokinetic and Pharmacodynamic Data.

Authors:  Jijie Li; Kewei Yan; Lisha Hou; Xudong Du; Ping Zhu; Li Zheng; Cairong Zhu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

9.  Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Authors:  Mats O Karlsson; Irja Lutsar; Peter A Milligan
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

10.  Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin.

Authors:  Mohammad I Saleh; Demet Nalbant; John A Widness; Peter Veng-Pedersen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-13       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.